Polypharmacy guidance: realistic prescribing
|
ACE |
Angiotensin Converting Enzyme |
|
ACEI |
Angiotensin Converting Enzyme Inhibitor(s) |
|
ACS |
Acute Coronary Syndrome |
|
ADR |
Adverse Drug Reaction |
|
AF |
Atrial Fibrillation |
|
AKI |
Acute Kidney Injury |
|
ARB |
Angiotensin II Receptor Antagonist |
|
ASB |
Asypmtomatic Bacteriuria |
|
BMI |
Body Mass Index |
|
BNF |
British National Formulary |
|
BNP |
Brain Natriuretic Peptide Test |
|
BP |
Blood Pressure |
|
BPM |
Beats per Minute |
|
CI or C.I. |
Confidence Interval |
|
CCBs |
Calcium Channel Blockers |
|
CHA2DS2-VASc |
Score for Atrial Fibrillation Stroke Risk |
|
CHD |
Coronary Heart Disease |
|
CHF |
Congestive Heart Failure |
|
CHI |
Community Health Index |
|
CKD |
Chronic Kidney Disease |
|
CNS |
Central Nervous System |
|
COPD |
Chronic Obstructive Pulmonary Disease |
|
CVA |
Cerebrovascular Accident |
|
CVD |
Cardiovascular Disease |
|
DMARDs |
Disease-modifying anti-rheumatic drugs |
|
DM |
Diabetes Mellitus |
|
DMT2 |
Diabetes Mellitus Type 2 |
|
DN4 |
Douleur Neuropathique 4 (Questionnaire used in diagnosis of neuropathic pain) |
|
DOACs |
Direct Acting Oral Anticoagulants |
|
ECG |
Electrocardiogram |
|
ECHO |
Echocardiogram |
|
EFIPPS |
Protocol for the Effective Feedback to Improve Primary Care Prescribing Safety |
|
eGFR |
Estimated Glomerular Filtration Rate |
|
FEV1 |
Forced Expiratory Volume-one second |
|
g |
Gram (unit of measurement) |
|
GI |
Gastro-intestinal |
|
GTN |
Glyceryl Trinitrate |
|
HbA1C |
[Refers to] glycated haemoglobin |
|
HDL |
High-density lipoprotein |
|
HF |
Heart Failure |
|
ICD-9 |
International Classification of Disease (Version 9) |
|
ICD-10 |
International Classification of Disease (Version 10) |
|
IHD |
Ischaemic Heart Disease |
|
INR |
International Normalised Ratio |
|
ISD |
Information Services Division |
|
L2 |
2nd Lumbar Vertebrae |
|
LANSS |
Leeds Assessment of Neuropathic Symptoms and Signs |
|
LFTs |
Liver Function Tests |
|
LVEF |
Left Ventricular Ejection Fraction |
|
LVSD |
Left Ventricular Systolic Dysfunction |
|
MAOIs |
Monoamine oxidase inhibitors |
|
mg |
Milligram (unit of measurement) |
|
MI |
Myocardial Infarction |
|
MMSE |
Mini-Mental State Examination |
|
MRI |
Magnetic Resonance Imaging |
|
NICE |
The National Institute for Health and Care Excellence |
|
NNH |
Number Needed to Harm |
|
NNT |
Number Needed to Treat |
|
Non-STEMI |
Non ST-elevation myocardial infarction |
|
NSAID |
Non-steroidal anti-inflammatory drugs |
|
NYHA |
New York Heart Association (Functional Classification) |
|
PIS |
Prescribing Information System |
|
POA |
Power of Attorney |
|
PPIs |
Proton Pump Inhibitors |
|
QTc |
Corrected QT Interval |
|
SIGN |
Scottish Intercollegiate Guidelines Network |
|
SMBG |
Self-Monitoring of Blood Glucose |
|
SMR01 |
Scottish Morbidity Record (Covers General Acute Inpatient and Day Case) |
|
SPARRA |
Scottish Patients at Risk of Re-admission or admission |
|
SSRI |
Selective Serotonin Reuptake Inhibitors |
|
STEMI |
ST-elevation myocardial infarction |
|
STU |
Scottish Therapeutics Utility |
|
TCA |
Tricyclic Antidepressants |
|
T Score |
Bone Density Score |
|
TFT |
Thyroid Function Test |
|
UTI |
Urinary Tract Infection |
|
U&E |
Urea & Electrolyte Profile |